NYSE:JNJPharmaceuticals
Johnson & Johnson (JNJ) Expands Tecvayli Approval In Europe For Multiple Myeloma
Johnson & Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI (teclistamab) plus daratumumab as a treatment for adult patients with relapsed or refractory multiple myeloma.
The decision extends the approved indication for TECVAYLI in Europe following Phase 3 data that showed significant survival benefits versus standard of care.
This expanded label adds a new therapeutic option within Johnson & Johnson's multiple myeloma portfolio and may influence its European oncology...